| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014031566 |
| P356 | DOI | 10.1007/S00520-011-1241-6 |
| P698 | PubMed publication ID | 21818641 |
| P50 | author | Alexandre Chan | Q45839458 |
| Sze Huey Tan | Q60061128 | ||
| P2093 | author name string | Raymond Ng | |
| Joen Chiang | |||
| Christy Chen | |||
| P2860 | cites work | Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial | Q31826097 |
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. | Q34555219 | ||
| Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study | Q34562182 | ||
| Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients | Q34566114 | ||
| Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients | Q35596990 | ||
| Role of anthracyclines in the treatment of early breast cancer | Q37581289 | ||
| Long-term toxic effects of adjuvant chemotherapy in breast cancer. | Q37834884 | ||
| Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. | Q40363722 | ||
| Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors | Q40516640 | ||
| Anthracyclines in the treatment of cancer. An overview | Q41637134 | ||
| Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass | Q42670935 | ||
| Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices | Q44691615 | ||
| Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. | Q46431139 | ||
| Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. | Q46890015 | ||
| Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up | Q72596355 | ||
| Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22 | Q73368640 | ||
| Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B | Q77156165 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1525-1532 | |
| P577 | publication date | 2011-08-05 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy | |
| P478 | volume | 20 |
| Q92798547 | A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients |
| Q98227876 | A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens |
| Q45203229 | Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden |
| Q86313597 | Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas |
| Q87334166 | Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients |
| Q88599453 | Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy |
| Q41484971 | Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study |
| Q38037349 | Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review |
| Q38109529 | Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia |
| Q36769011 | Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy |
| Q92759656 | Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer |
| Q38772800 | Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis. |
| Q38682028 | Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis |
| Q91793857 | Melioidosis with Septic Shock and Disseminated Infection in a Neutropenic Patient Receiving Chemotherapy |
| Q90148020 | Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study |
| Q55322325 | Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. |
Search more.